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Abstract
Interest in “engineering liver” arises from multiple communities: therapeutic replacement;
mechanistic models of human processes; and drug safety and efficacy studies. An explosion of
micro- and nano-fabrication, biomaterials, microfluidic, and other technologies potentially afford
unprecedented opportunity to create microphysiological models of human liver, but engineering
design principles for how to deploy these tools effectively towards specific applications, including
how to define the essential constraints of any given application (including available sources of
cells, acceptable cost, and user-friendliness) are still emerging. Arguably less appreciated is the
parallel growth in computational systems biology approaches towards these same problems –
particularly, in parsing complex disease processes from clinical material, building models of
response networks, and in how to interpret the growing compendium of data on drug efficacy and
toxicology in patient populations. Here, we provide insight into how the complementary paths of
“engineering liver” – experimental and computational – are beginning to interplay towards greater
illumination of human disease states and technologies for drug development.
Therapeutic tissue engineering
The field of therapeutic tissue engineering took off about 25 years ago, with early
demonstrations showing how combining donor cells with synthetic degradable polymer
scaffolds could lead to regeneration of tissue, such as cartilage in the shape of a human ear
(1). This sparked excitement that similar approaches could be applied to either transplant
hepatocytes on scaffolds or to build livers ex vivo for transplantation. In the ensuing two
decades, lab-grown bladders and tracheas have made it to the clinic – why not liver?
Intuitively, both the degree of structural complexity, with finely interwoven vascular,
biliary, and lymph networks, as well as its sheer size and vascularity make ex vivo liver
engineering vastly more challenging. Scaffolds for growing trachea and bladder can be made
as simple stacked layers and nurtured in bioreactors that flow fluid over the tissue. In
contrast, in addition to the intricate structural complexity, the functions of liver depend on
intimate close contact of hepatocytes with local flow of blood, hence scaffold complexity
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and local tissue microperfusion are intimately intertwined in creating and maintaining
functional “liver”. Presuming the availability of the relevant constituent source cells,
“engineering liver” thus requires not only more sophisticated tools – biomaterials, methods
of scaffold fabrication, bioreactors – but also more sophisticated quantitative design
principles for how to use the tools to drive creation of tissue (2).
While it is debatable whether building lab-grown livers for transplant remains a realistic
goal, the vision of doing so helped drive development of myriad biomaterials and
microfabrication tools. We first take stock of the state of the art solid free-form fabrication
(SFF) technologies for building 3D scaffolds (1,3) (see Supplemental Material for details of
methods and caveats) and then discuss biomaterials and bioreactors. All SFF methods build
complex 3D objects as a series of thin (10-200 um) layers, guided by computer programs
that direct creation of complex features within each layer (4-6). Most methods make
scaffolds or sacrificial molds, though they can also be used to manipulate the cells
themselves, maintaining cell viability with varying degrees of success(6). Examples of these
processes include: 3D Printing, which involves depositing material from a nozzle into the
“build” layer, where the layer may contain either a fine powder that is gelled or bonded by a
printed liquid or may contain a support material to catch cells printed directly from the
nozzle; stereolithography, a layer-by-layer process in which (UV) light is used to polymerize
macromers by illuminating only selected regions of a thin layer of precursor solution (which
may contain cells); and variations combinations of these (5-7). Although SFF methods are
permeating many consumer product domains from fashion to guns, tissue engineering
applications remain highly demanding due to the desire for control over both very small
length scales (~10 um) and larger scales (100-1000 um) in the same object, the inverse
relationship between how long it takes to build an object and the fineness of the length scale,
and the sensitivity of cells to polymerization processes and movement through nozzles. For
example, while direct printing of cells is conceptually attractive, and an approach based on
printing dense liver cell suspensions supported by inert agarose co-printed as a physical
support to guide formation of 3D tissues results in formation of viable tissue structures, the
structures are relatively large (300 um) (8). Methods to develop finer structures by (for
example) perfusion in bioreactors are still evolving, as the challenges in directing
morphogenesis of fine features along with providing appropriate distribution of oxygen and
signaling molecules are not trivial (2). A path to accomplishing the fine scale has recently
been applied to creating microscale perfused vascular liver structures by extrusion of arrays
of molten sugar cylinders, which can subsequently be infused with gel suspensions
containing cells, dissolving the sugar to yield perfusable channels that can be lined with
endothelial cells and has shown promise for creating vascularized structures in vitro that can
be transplanted in vivo (9).
Arguably, the vision that spurred development of new tissue engineering technologies –
creation of transplantable livers - is being eclipsed by the goal of deploying tissue
engineering to understand, prevent, and cure liver injury and disease. Many confluent forces
have pushed the field incrementally in this direction. On the therapeutic front, steady
progress is being made on understanding and treating liver diseases that ultimately cause
liver failure, and in stabilizing patients with late-stage disease. Although extracorporeal
support devices have not yet shown a strong benefit in improving patient survival (10),
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hepatocyte transplantation to treat cirrhosis and other diseases is moving closer to clinical
reality (11). At least one human clinical trial using donor-derived hepatocytes showing that
the procedure is not only safe but can have a beneficial effect on cirrhotic patients (12). A
side consequence of therapeutic cell transplantation is development of protocols for creating
mice with humanized livers, which despite certain limitations as a model for liver
pathophysiology and drug development broadly, are gaining traction for study of infectious
disease(13). At the same time that new drugs and drug regimens for managing progression
of hepatitis may chip away at some of the clinical need, the tremendous progress in
understanding fibrotic processes in general, and liver in particular, stokes optimism that
together with earlier diagnosis, new therapies for fibrotic diseases that cause so much
clinical devastation may truly be in sight (14,15). The major push, though, is the increased
demand for human in vitro models in all phases of the drug discovery and development
process (1).
In Vitro Models
The mouse is increasingly under attack for failing as an adequate model of human
physiology and disease, let alone for assessing drug metabolism and toxicity, responses to
chemotherapy agents and biotherapeutics – not to mention for being an expensive, high
maintenance tool for research and discovery. Enter “tissue engineered” human in vitro
models – which are still quite nascent and limited for widespread use, but which have
promising futures. Realization of complex models is enabled in part by increasingly
sophisticated experimental tools for constructing controlled cell and tissue micro-
environments, but also a growing appreciation for the quantitative rules that govern how
cells (and tissues) integrate chemical and mechanical cues across many length and time
scales to generate a basal phenotype and to respond to microenvironmental perturbations
(2,16). Indeed, relatively straightforward experimental tools can be transformed by
quantitative analysis into in vitro models that are high impact because they are both
accessible to a wide community (i.e., biology labs) and they conceptually capture a complex
in vivo situation. An elegant example is the study of fibrosis, where a popular, accessible
“tissue engineering tool” – 2D polyacrylamide gel substrates that can be tuned to specific
bulk stiffness and modified with various ECM molecules – is being deployed to illuminate
how matrix stiffness interplays with chemical cues to drive fibrotic phenotype of stellate
cells as illustrated in Figure 1 (17). Matrix stiffness, together with biophysical presentation
mode of epidermal growth factor (EGF) in concert with integrin ligands also influences
morphogenesis, proliferation, and differentiation of primary hepatocytes in quasi 2-D culture
(18). Moving into more physiological 3D environments requires attention to multiple
variables at once: degradability, stiffness (at bulk and molecular scales), permeability, and
bioactive ligands. Synthetic and semi-synthetic gels for controlling such variables are slowly
moving from specialty labs that develop them into use in liver tissue engineering through
iterative processes of design, phenomenological impact on phenotype, and translation to
commercial availability (see Supplemental Material). An example of this process is the
recent demonstration, using commercially-available hyaluronan gels, that 3D matrix
stiffness influences differentiation of hepatic progenitors (19). A host of molecular-to-
macroscale design principles are emerging from the biomaterials community to further
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improve how materials function for controlling dynamic processes such as migration and
morphogenesis. For example, nanoscale clustering of ligands, compared to random
presentation, can dramatically influence cell migration speed (20), the stiffness of tethers
between adjacent FNIII 9-10 domains can influence integrin specificity and epithelial
differentiation (21), localized gel degradation and ensuing enhanced traction can change
differentiation fate of stem cells independent of matrix stiffness (16), and gradients in matrix
stiffness can direct capillary morphogenesis in vitro as illustrated in Figure 1 (22). Further,
ECM also acts as a depot for autocrine ligands in a sort of “cell sonar” fashion, a property
that is now being productively exploited by incorporation of specific growth factor binding
domains to control localized concentrations of factors (23). These design principles are
being incorporated together into synthetic and semisynthetic gels in systematic fashion to
allow translation to the general biology community (24,25). Isolated liver cells can also use
geometric cues from macroporous 3D scaffolds to self-organize into 3D tissue-like
structures, guided by the balance of cell-cell and cell-substrate adhesion (26). A more
detailed summary of how these approaches are being applied to liver cell and tissue culture
is provided in the online Supplemental Material Section B and in other recent reviews
(4,27).
How close are we to a true 3D sinusoid model of fibrosis? If we presume that the constituent
cells are available and simply need to be assembled properly, a combination of biomaterials
and microreactor technologies are converging to make this at least theoretically possible,
though making all the parts work together quantitatively – and in an accessible format – is
an evolutionary process. Arguably, a starting point is the work with 100-250 um thick liver
slices, which contain all the constituent non-parenchymal cells in a relatively quiescent state
and can recapitulate stellate cell activation and other early inflammatory responses to pro-
fibrotic stimuli (28-30) as well as complex mechanisms of metabolism and toxicological
responses to drugs (31). Although slice cultures likely have enduring utility due to their high
functionality and the reproducibility of creating large numbers of slices from scarce donor
material, their survival is typically limited to a few days, (presumably due to limitations in
oxygen and regulatory molecule diffusion) even when placed in an environment with
controlled perfusion around the slice and further physically stabilized in the flow by addition
of matrigel, which may also enhance the phenotypic stability of cells at the slice surface
(32). It is possible that the missing essential ingredient is local sinusoidal microperfusion
through the slice, which serves not only to distribute oxygen and nutrients but also provides
essential mechanical stimuli to tissues in part through interstitial flow from capillaries to
lymph(2). It is interesting to speculate that, if placed in a flow upstream of a suitable
biomaterial gel, microvessels in slices might shift to align with microperfusion and
demonstrate tissue outgrowth, though matching the time scales for tissue survival with those
for such tissue remodeling, may be a barrier. Hence, approaches based on tissue assembly
from isolated cells together with microfluidics are a more commonly-pursued approach to
make tissue structures. Classic microfluidics approaches employ simple molding methods to
create intricate designs of interconnected channels and chambers in silicone rubber (PDMS)
slabs bonded to glass, with feature sizes ranging 1 um - 10 mm, allowing precise control of
fluid flow and associated molecular transport between adjacent fluid streams and
compartments (33) (see Supplement Section C). A microfluidic device that creates sinusoid-
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size (55 × 80 × 3000 um) quasi-3D cords of hepatocytes separated from a fluidic channel by
a porous PDMS “sinusoid membrane”, enabling maintenance of hepatocellular functions
(34) (Figure 2) has been adapted to a multi-well format commercially, with a caveat that
PDMS is highly absorptive to many lipophilic drugs and steroid hormones. A spectrum of
related designs that organize hepatocytes into cord-like structures surrounded by
microchannels that control molecular and fluid transport and maintain tissue-like structure/
function have been described (33,35) (Figure 2). These hepatocentric models were geared
toward applications in drug development – metabolism, toxicity, and possibly bile transport
or small molecule drugs (“ADME-tox”) – though are now being deployed to create
organoid-like hepatocyte-NPC structures (36). Further, we are still learning about how
subtle changes in parameters like interstitial-level fluid flows influence the biology of
endothelium and the underlying tissues, hence comparison of the desired phenotype against
in vivo counterparts in an iterative fashion is crucial (2,37).
As with microfabrication methods, the goal of building therapeutic technologies has driven
innovation in design of bioreactors for maintaining highly metabolically-active liver tissue,
for example in scaling down clinical-size hollow fiber reactors to miniature versions, though
these remain complex for general use (38) (Figure 2). The limitations of PDMS and
microfluidics has also led to development of other user-friendly microscale liver reactors
that foster long term viable co-cultures of hepatic tissue-like structures, including liver
sinusoidal endothelial cells in the absence of VEGF, and that are made from material with
less propensity to adsorb hydrophobic molecules than PDMS and with an open platform to
facilitate cell seeding and to accommodate larger tissue structures (39) (for a comprehensive
review of liver bioreactors, see (40)). This increased tissue mass and depth allows studies to
extend beyond liver-only pathologies, for example, study of micrometastasis homeostasis in
human tissue (41). Another example of a tissue engineered disease model is the use of 2D
micropatterned hepatocyte-fibroblast cultures for analysis of HCV life cycle(42), where
fibroblasts stabilize liver function. This format is commercially available though has not yet
been widely adapted for in vitro analysis of HCV, perhaps due to the complexity of
questions regarding immune function contributions and other factors that require
idiosyncratic development of in vitro models of HCV to address specific questions including
the role of cell polarization(43,44). Thus, the goals of “engineering liver” have moved
beyond even the secondary development of ex vivo relevant models of liver function, to
aspirations of understanding of systemic diseases.
Assemble it or let it develop?
Most tissue engineering approaches involve reconstructing tissues using dissociated cells.
More recently, organogenesis from stem cells is emerging as a viable alternative route (45).
A dramatic example is generation of human intestinal organoids, from iPS cells, comprising
all the intestinal epithelial cells types plus intestinal mesenchyme and smooth muscle, villus-
like structures with CDX2 expression, secretory and excretion function (46). These
organoids exhibit substantial function without vascular perfusion, but liver is likely more
intimately co-dependent on vascular development and perfusion as embryonic development
of the liver bud requires signals from endothelial cells (47), and efficient protocols for in
vitro differentiation of ES cells to hepatocytes result in co-appearance of endothelial cells
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(48). Encouragingly, spontaneous formation of vascularized “liver bud” structures have been
observed when human iPS-derived hepatic-specified cells (immature endomermal cells
destined to track to the hepatic cell fate) are combined in vitro with human umbilical vein
endothelial cells (HUVEC), and these structures form patent vascularized vessels when
transplanted in vivo, improving liver-specific differentiation (49). Combinations of
microscale perfusion technologies and biomaterials may help drive morphogenesis into a
functional perfused microtissue in vitro, if the morphogenesis cues can be quantitatively
presented (45,50). Nascent efforts to capture similar interactions in terms of computational
modeling morphogenesis of endothelial-cell dependent developmental differentiation is
being applied to pancreas (51) and other stem cell differentiation processes (45). A
tremendous challenge in computational modeling of developmental morphogenesis is
capturing the interplay between processes wherein co-dependent intracellular and
extracellular chemical and mechanical cues are integrated in dynamic fashion, and
understanding how faithfully these models recapitulate the process requires experimental
validation. While these systems (liver and pancreas) offer substantial experimental
challenges at the present time, dramatic examples of how mathematical models can capture
complex developmental processes have recently been described in more tractable
experimental systems, such as the development of mammalian teeth (52) and whole
organismal differentiation of drosophila (53). The merging of quantitative insights from both
traditional tissue engineering approaches and developmental biology is just starting and will
likely foster substantial evolution in the design of experimental tools.
What to model? Tissue engineering meets systems biology
The methods for making tissue ever more complex are evolving in tandem with approaches
for deconstructing complex problems and making them ever more tractable experimentally.
Engineering almost always invokes images of “building” (or designing and building), but
engineering is equally about framing problems in ways that allow them to be solved with the
minimal possible experimentation, by using mathematical analysis to understand complex
systems.
One of the biggest demands for in vitro liver models is in assessing drug-induced liver injury
(DILI) early in the development process before proceeding to clinical trials. A variety of
new computational models built in part on mining clinical data and in part on designing
mechanistic experiments based on patient data are continually shaping the landscape of what
is desirable experimentally (54,55). For example, one of the most difficult types of DILI to
predict is idiosyncratic toxicity, which appears late in clinical trials. Among the mechanisms
that might give rise to such adverse events in humans include rare alleles for metabolic or
transport enzymes, hypersensitive immune network responses, and interaction of drug
metabolism with mild liver inflammation that arises from transient increases in gut
permeability and specific microbiome products. While the liver slice models described
above capture facets of these NPC-mediated events that are not represented in standard
hepatocyte cultures (31), computational modeling of inflammation provides insights into
experimental conditions that can drive hepatocentric experimental models into inflammatory
states, offering additional high-throughput approaches to screening (56). The in vivo
situation is complex especially when including the invasion of immune cells, a high-
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throughput 96-well plate assay based on dosing primary hepatocytes with combinations of
cytokines and drugs captured a significant fraction of idiosyncratic toxins from a list of 90
drugs with known clinical outcomes; moreover, consensus signaling pathways were
identified in toxic outcomes by computational analysis of time-dependent activity of
multiple kinase signaling nodes (56), and the approach was extended into a 3D co-culture
model as a step toward incorporating greater complexity of the immune response(57).
Immune system signatures have also been revealed in genome-wide association studies of
idiosyncratic toxicity of several drugs (58), suggesting mechanisms that would like be
difficult to detect with any current in vitro assay. A powerful new approach for analyzing
post-market surveillance data to account for sparse information and co-variation of factors in
large clinical trials that permits the identification of drug targets, prediction of drug
indications, and discovery of drug-class interactions may allow further inroads in
understanding DILI (59).
Finally, multiscale systems biology approaches applied in an iterative fashion to patient
samples, animal models, and in vitro data, are making inroads on the complex immune
networks that underlie chronic inflammatory diseases and pointing the way to therapeutic
intervention at non-intuitive targets. A recent example is the first illustration of how
quantitative analysis of extracellular cytokine networks, intracellular signaling networks,
and temporal evolution in cell phenotypic behaviors (apoptosis, proliferation, immune cell
invasion, cascades of cytokine secretion by immune and epithelial cells) sensitizes the
intestinal epithelium to TNF-α-driven apoptosis in vivo (60). While it is unclear precisely
where the inferences from such multiscale analysis of in vivo data will drive the
development of human microphysiological systems, it underscores the necessity of including
trafficking of various circulating cells into and out of the tissue analogues – as well as cross
talk with other organ systems through cytokines and other types of molecular signals. Many
of the drugs that might intervene in this cascade are biologics – underscoring that many of
the emerging challenges in both efficacy and toxicology center on predicting behavior of
biologics, particularly how they affect the non-target cells in both direct and indirect
(paracrine-mediated) manner.
Future Challenges and Opportunities
Three common threads running through the technical analysis above point to barriers in
“engineering liver” to solve the problems outlined in the introduction: (i) there are many
diverse applications with different technical needs, creating a fragmented set of approaches
with only partial overlap in efforts toward common problems in the field (ii) any complex
model requires a team with substantial breadth of scientific and technical expertise (and
related financial resources) to design, build and test the model and (iii) bridging the gap
between proof-of-principle that a model or therapy works in a research setting and that it
works in the ultimate user community usually requires substantial commercial investment to
“productize” and disseminate the approach, and is usually not until the model is test run in
multiple different environments that the true utility and economic sustainability is known,
and in the process, the model made be made partially redundant or obsolete by other
simpler, more cost-effective approaches. Extracorporeal liver support bioreactors are an
example of well-engineered technology that has not shown a strong, clear-cut advantage
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over less costly alternatives. The application landscape is still sorting out for several
microfabricated and microfluidic-type liver culture devices that are commercially available
or are in development, including the Hμrel chip (monolayer micropattered co-culture),
HepatoPac (monolayer micropatterned co-cultures), In Sphero (hanging drop spheroid
culture), Regenemed (3D scaffold-supported culture), CN Bio Innovations (3D microscale
reactor), the Pearl system by CellAsics/Millipore (device for microfluidic culture in a
sinusoid configuration), and OrgoNova scaffold-free tissue. Although many of the
envisioned applications of these technologies are in pre-clinical drug development for
ADME/Tox, the advantages they offer are still sorting out (see recent reviews (27,40)); for
example, although the extended functional longevity of engineered systems appears
conceptually attractive as a way to measure clearance of drugs that are metabolized very
slowly, clearance of a substantial fraction of such low clearance compounds can be captured
using sequential incubations with more traditional hepatocyte preparations (61). A clear
challenge shared by all engineered systems is the availability of various liver cells as
“reagents” that are broadly accessible (commercially or otherwise), reproducible, and cost-
effective to deploy. All cell lines, while useful for certain targeted purposes, have some
drawbacks in representing liver physiology broadly (powers), and of the many cell types in
liver, only hepatocytes and Kupffer cells are routinely commercially available in
cryopreserved form; many cells, particularly the sinusoidal endothelial cells, are relatively
fragile and resistant to cryopreservation approaches. The tremendous progress in deriving
hepatocyte-like cells from stem cells appears on the verge of yielding robust supplies, but if
the argument that engineered systems are tailored for illuminating more complex
physiologies, particularly those involving immune function or higher-order interactions
among hepatocytes and NPC, then reliable sources of NPC and immune cells are also
needed.
It is interesting to speculate that the organogenesis approaches may ultimately yield at least
partial breakthroughs – indeed, co-evolution of hepatocytes and NPC in an organoid format
may foster more robust maturation of hepatocyte-like cells, and at the same time provide a
source of at least some NPC; though the origins of some NPC are debated (62). It is also
interesting to further speculate that engineered devices and biomaterials – together with
quantitative “design principles” – may boost the prospects of success in organoid
development, by providing control of external cues, particularly mechanical forces including
flow.
Finally, regardless of the evolution in sophistication of experimental systems, continued
progress is needed on the “reverse engineering” of complex cell-cell communication and
signaling networks in patient samples; i.e., to build quantitative models of disease
pathogenesis so that the best targets in complex networks can be identified.
In summary, the combined computational and experimental approaches to “engineering
liver” will surely continue to yield rich new insights, at least incrementally. There is great
potential for synergy between these that will accelerate the pace, and we look forward
optimistically to the continued blending of these two ends of the “liver engineering”
spectrum.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Designer Synthetic Extracellular Matrix (ECM) Materials Allow Control of Matrix
Stiffness, Permeability, and Selective Adhesion and Growth Factor Interactions. (A) ECM-
modified polyacrylamide gels tuned to soft, moderately stiff, and stiff bulk elastic moduli
reveal the role of ECM mechanical properties on activation of hepatic stellate cells [from
(22)]; (B) Matrix-tethered EGF, compared to soluble EGF, dramatically alters phenotypic
responses of hepatocytes on self-assembling peptide hydrogels with tuned bulk elastic
moduli [from (23)]; (C) Schematic illustrating modular design of synthetic 3D hydrogels for
cell encapsulation or invasion. Gels comprise a structural water-soluble polymer (such as
polyethylene oxide, dextran, hyaluronic acid, etc) crosslinked by Michael addition, photo-
polymerization, temperature- or ion-induced phase change, or enzymatically, and with
modules including selective protease cleavage sites and tethered adhesion or growth factor
ligands or motifs that bind to matrix or growth factors. The crosslink density and choice of
polymer influence the permeability (characterized by a “mesh size” typically on the scale of
nm) and the bulk mechanical properties, while local mechanical properties sensed by
receptors are also influenced by the tether length, stiffness, and ligand orientation or
clustering. (D) Example of directed angiogenesis by endothelial cells encapsulated in a
synthetic RGD-modified PEG gel. Cells encapsulated in an isotropic gel exhibit isotropic
orientation of capillary tubes, while cells encapsulated in a gel with a stiffness gradient show
oriented tube formation. [from (27)].
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Figure 2.
Microscale bioreactors to control hepatic tissue organization and flow. (A) Microfluidic
design to mimic flow and gradients along an hepatic sinusoid, with dual flow networks to
enable easy loading with a precise number of hepatocytes [from (33)]. Shown is the
research-scale precursor to the commercially available multi-reactor chip version. (B)
Microfluidic reactor design for examining how mechanical compaction of cell aggregates
during tissue formation influences tissue morphogenesis, including formation of biliary
networks [from (35)] (C) Multi-well plate bioreactor system that fosters 3D tissue-like
formation in an array of channels of a “chip” scaffold seeded with isolated liver cells, where
microscale flow is maintained by a microfluidic pump; images at the top show individual
300 um-diameter channels containing tissues formed from co-cultures of hepatocytes with
non-parenchymal cells, and treated with either drug alone (left), inflammatory cue alone
(middle) or a combination, then stained with live (green) /dead (red) dyes, illustrating
synergy between inflammation and drug metabolism in hepatotoxicity [from (52)].
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